Table 2.

Results of the post-treatment VIA/Pap smear/HR-HPV and subsequent histological confirmation.

	Overall (N=517)	Total histology (N=248)	Histology
			Normal (N=126)	CIN I (N=50)	CIN II (N=25)	CIN III (N=41)	CIS (N=4)	Cancer (N=2)
Cytology
Inadequate	39(7.5%)	17	9(52.9%)	2(11.8%)	2(11.8%)	4(23.5%)	0 (0%)	0 (0%)
Normal	398(77.0%)	173	98(56.6%)	42(24.3%)	9 (5.2%)	20(11.6%)	3(1.7%)	1(0.6%)
ASCUS	7 (1.4%)	3	1(33.3%)	0 (0%)	1(33.3%)	1(33.3%)	0 (0%)	0 (0%)
LSIL	26 (5.0%)	18	5 (27.8%)	2(11.1%)	6(33.3%)	5 (27.8%)	0(0%)	0(0%)
HSIL	45(8.7%)	35	12(34.3%)	4(11.4%)	7(20%)	11(31.4%)	0(0%)	1 (2.9%)
Cancer	2(0.4%)	2	1 (50%)	0 (0%)	0(0%)	0(0%)	1(50%)	0(0%)
VIA
Positive	100(19.3%)	81	40(49.4%)	19(23.5%)	9(11.1%)	12(14.8%)	0(0%)	1(1.2%)
Negative	417 (80.7%)	167	86(51.5%)	31(18.6%)	16 (9.6%)	29(17.4%)	4 (2.4%)	1 (0.6%)
HR-HPV positive
Positive	275(53.2%)	214	107(50%)	45(21%)	20(9.3%)	36(16.8%)	4(1.9%)	2(0.9%)
Negative	242 (42.8%)	34	19(55.9%)	5 (14.7%)	5(14.7%)	5(14.7%)	0(0%)	0 (0%)
VIA/PAP/HPV
--/--/--	174(36.4%)	0	-	-	-	-	-	-
--/--/+	163(34.1%)	122	69(56.6%)	28(23%)	7(5.7%)	14 (11.5%)	3 (2.5%)	1 (0.8%)
--/+/--	20(4.2%)	10	4 (40%)	0(0%)	3 (30%)	3(30%)	0 (0%)	0 (0%)
--/+/+	32(6.7%)	26	9(34.6%)	2 (7.7%)	5 (19.2%)	9 (34.6%)	1(3.8%)	0(0%)
+/--/--	26(5.4%)	17	12 (70.6%)	5 (29.4%)	0 (0%)	0 (0%)	0(0%)	0(0%)
+/--/+	42(8.8%)	37	18(48.6%)	9 (24.3%)	3(8.1%)	7(18.9%)	0(0%)	0(0%)
+/+/--	4(0.8%)	4	1(25%)	0(0%)	1 (25%)	2(50%)	0(0%)	0(0%)
+/+/+	17(3.6%)	15	4 (26.7%)	4(26.7%)	4(26.7%)	2(13.3%)	0(0%)	1(6.7%)
Any test positive	304(63.6%)	231	117 (50.6%)	48(20.8%)	23 (10%)	37 (16%)	4(1.7%)	2(0.9%)
All tests positive	17(3.6%)	15	4 (26.7%)	4(26.7%)	4(26.7%)	2(13.3%)	0(0%)	1(6.7%)